Article Text

Download PDFPDF
Correspondence
Authors response. The chronic obstructive pulmonary disease (COPD) control panel: towards personalised medicine in COPD
  1. Alvar Agusti1,2,
  2. William MacNee3
  1. 1Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
  2. 2FISIB, CIBER Enfermedades Respiratorias Mallorca, Spain
  3. 3ELEGI Colt Laboratories, MRC/UoE Centre for inflammation Research, Queen's Medical Research Institute, Edinburgh, UK
  1. Correspondence to Professor Alvar Agusti, Thorax Institute, Hospital Clinic, University of Barcelona, IDIBAPS, Villarroel 170, Escala 3, Planta 5, Barcelona 08036, Spain and and FISIB, CIBER Enfermedades Respiratorias Mallorca, Spain; alvar.agusti{at}clinic.ub.es

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We thank Dr Vishnivetsky et al 1 for their interest in our paper on the ‘COPD control panel’. We are happy to see that our proposal has generated some debate. In their letter, Dr Vishnivetsky and colleagues raise several important issues: (1) Relevance of comorbidities. We fully agree with their comments. Whether or not they should be ‘prioritised’ in the control panel proposed is open for debate. …

View Full Text

Footnotes

  • Contributors Both authors contributed equally to this paper and to the response to the Letter to the Editor.

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles